By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


SEARCH JOBS

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.

YEAR FOUNDED:

1980

LEADERSHIP:

CEO: Ed Kaye, M.D.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: avi@avibio.com
Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT
 



Industry
Biotechnology






Company News
Sarepta (SRPT) Announces Positive Results In Its Study Evaluating Gene Expression, Dystrophin Production, And Dystrophin Localization In Patients With Duchenne Muscular Dystrophy (DMD) Amenable To Skipping Exon 53 Treated With Golodirsen (SRP-4053) 9/6/2017 10:30:41 AM
Sarepta (SRPT) To Ring Nasdaq Stock Market Closing Bell In Recognition Of World Duchenne Awareness Day 9/6/2017 8:54:42 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/1/2017 7:54:50 AM
Sarepta (SRPT)’s Exondys 51 Saga Continues as More Details About FDA’s Criticism Uncovered 8/22/2017 6:17:53 AM
FDA Docs Reveal CDER Chief Skirted Procedures Approving Sarepta (SRPT)'s Controversial Drug Eteplirsen 8/3/2017 8:21:17 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 8/1/2017 1:13:11 PM
Sarepta (SRPT) Announces Its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data In Nature Communications 7/27/2017 11:00:35 AM
Sarepta (SRPT) Announces Pricing Of $325 Million Public Offering Of Common Stock 7/25/2017 1:10:12 PM
Sarepta (SRPT) Announces Proposed $250 Million Public Offering Of Common Stock 7/24/2017 11:06:38 AM
Sarepta (SRPT) Secures $100 Million In Debt Financing 7/19/2017 11:15:38 AM
12345678910...
//-->